Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA clears Lumenis' IPL (Intense Pulsed Light) technology for rosacea:

This article was originally published in Clinica

Executive Summary

Lumenis has received US FDA 510(k) clearance to market its Intense Pulsed Light (IPL) technology as a treatment for hyperpigmentation and erythaema (redness) associated with the skin condition rosacea. IPL supplies high levels of non-laser light power in precision-measured pulses, controlled down to the ten-thousandth of a second. The Santa Clara, California firm says that according to the American Academy of Dermatology, around 13 million people in the US suffer from rosacea.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel